Skip to main content

Type 1 Diabetes News

Type 1 Diabetes is a chronic condition in which your body loses the ability to produce insulin, which is necessary for most cells to convert food into energy and regulate blood sugar levels. 

One Drop’s Chrome becomes the first blood glucose meter to send data directly to Apple Watch without a nearby phone. Plus, new health features on the Series 4 Apple...
Read about Kelly’s better quality of life on Loop, as well as the difficulties that ultimately ended her Looping experience; part 2 of a series on a hybrid-closed-loop...
DIY Loop virtual study requires no in-person visits and seeks 300-1,000 Loop users, especially those new to Looping. Data will support eventual FDA submission of...
In Canada, the G6 is expected to launch in late 2019 with no fingersticks and 10-day wear
Big focus on heart health outcome trials with PIONEER 6 and CAROLINA in the spotlight; plus promising CGM data in adolescents with type 1 diabetes
News from Onduo's virtual diabetes clinic, Klue, SugarMate, and Diabits apps, Tidepool Loop, and more!
When will we see a 670G with Bluetooth and remote monitoring? Also, the upcoming MiniMed 780G with automatic boluses, a seven-day wear infusion set, and better Medtronic...
The most promising therapies in the pipeline, accuracy data on the FreeStyle Libre 2, and more
MiniMed 780G to add automated correction boluses and Bluetooth, aims to launch by April 2020; Guardian Connect users can now use IQcast on Apple iPhones
CVS now offers same-day prescription home delivery from 6,000 pharmacies across the United States for a delivery charge of $7.99.
FreeStyle Libre 14-Day Now Available, G6 ships to Medicare users in early 2019
The ambitious national research program launched in 2018; how far has it come, and what will come out of it?
Dr. Diana Isaacs on CGM, “shared” appointments, and identifying “Bright Spots” and “Landmines.” Plus, how to find a Diabetes Care and Education Specialist near you
SGLT-1/2 therapy for type 1 diabetes, hybrid closed loop systems in teens and children, and the importance of glucose control as an outcome in addition to A1C!
The EMA approved Zynquista (sotagliflozin), an SGLT-1/2 dual inhibitor, for adults with a BMI above 27
Insightful diabetes leaders discuss high-potential areas ranging from SGLT-2s in type 1 diabetes, personalized treatment plans, and the do-it-yourself Loop app
Called “Insulin Lispro,” the generic version of Humalog may benefit those paying cash or with high-deductible health plans
A recent study found 38% of those with type 1 diagnosed after age 30 were not initially given insulin; learn ways of differentiating between type 1 and type 2 at...
JDRF Chief Mission Officer Dr. Aaron Kowalski has been named the organization’s next President and CEO. See our exclusive interview with Dr. Kowalski!
If approved, Lilly’s intranasal glucagon would be a radical ease-of-use improvement over current glucagon kits for severe hypoglycemia

Pages